更新于：2024-12-10
Lascufloxacin Hydrochloride
更新于：2024-12-10
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C21H24F3N3O4 |
InChIKeyZFIOCUITTUUVPV-MEDUHNTESA-N |
CAS号848416-07-9 |
关联
36
项与 Lascufloxacin Hydrochloride 相关的临床试验Study protocol: Evaluation of efficacy and safety of Lascufloxacin in switch therapy for community-acquired pneumonia: a single arm, open-label clinical trial
Study protocol: Evaluation of efficacy and safety of Lascufloxacin for Nursing and Healthcare Associated Pneumonia: single arm, open-label clinical trial
Lascufloxacin penetration into otorhinolaryngological tissues study - LSPOT Study
100 项与 Lascufloxacin Hydrochloride 相关的临床结果
登录后查看更多信息
100 项与 Lascufloxacin Hydrochloride 相关的转化医学
登录后查看更多信息
100 项与 Lascufloxacin Hydrochloride 相关的专利（医药）
登录后查看更多信息
24
项与 Lascufloxacin Hydrochloride 相关的文献（医药）2024-09-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Lobar pneumonia due to human metapneumovirus: a case report
Article
作者: Kawataki, Masanori ; Koyama, Takashi ; Ito, Akihiro ; Ishida, Tadashi
Human metapneumovirus (hMPV) is a respiratory pathogen that can cause lower respiratory tract infections and pneumonia in immunocompetent adults. Pneumonia caused by hMPV is reportedly more likely to cause bronchial wall thickening and ground-glass opacity (GGO). A 44-year-old woman with no significant medical history developed fever, cough, and nausea. Computed tomography of the chest showed scattered GGOs in the right upper lobe and infiltrating shadows with air bronchograms in the left lingual and bilateral lower lobes. The patient was admitted to our hospital for further evaluation. Atypical pneumonia was suspected and lascufloxacin (LSFX) was started. Multiplex polymerase chain reaction (PCR) detected hMPV on hospital day 2 using the FilmArray Respiratory Panel 2.1. Pneumonia due to hMPV was suspected and LSFX was discontinued. The patient subsequently showed spontaneous improvement and was discharged on hospital day 6 after admission. After discharge, pneumonia continued to improve. Early detection of respiratory pathogens using multiplex PCR can help determine the appropriate treatment strategy. As hMPV can also cause lobar pneumonia, we should consider pneumonia due to hMPV in the differential diagnosis of lobar pneumonia.
2024-07-01Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Efficacy and safety of lascufloxacin for nursing- and healthcare-associated pneumonia: A single-arm, open-label clinical trial
Article
作者: Sasaki, Eisuke ; Izumikawa, Koichi ; Funada, Midori ; Imamura, Yoshifumi ; Morio, Ryosuke ; Irifune, Satoshi ; Futsuki, Yoji ; Fukuda, Yuichi ; Nemoto, Kazuki ; Kondo, Akira ; Hata, Ryosuke ; Iwanaga, Naoki ; Inoue, Yuichi ; Harada, Yosuke ; Yanagihara, Katsunori ; Ide, Shotaro ; Fukushima, Koki ; Takeda, Kazuaki ; Nagayoshi, Yosuke ; Shimabukuro, Ikuko ; Fukushima, Kiyoyasu ; Hanaka, Tetsuya ; Ito, Yuya ; Yoshida, Masataka ; Morikawa, Toru ; Tanaka, Hikaru ; Miyamura, Takuto ; Sawai, Toyomitsu ; Morimoto, Shimpei ; Hosogaya, Naoki ; Takazono, Takahiro ; Yatera, Kazuhiro ; Ota, Kenji ; Nakada, Nana ; Mukae, Hiroshi ; Suyama, Naofumi ; Mihara, Tomo
BACKGROUND:
Nursing- and healthcare-associated pneumonia (NHCAP) constitutes most of the pneumonia in elderly patients including aspiration pneumonia in Japan. Lascufloxacin (LSFX) possesses broad antibacterial activity against respiratory pathogens, such as Streptococcus spp. And anaerobes inside the oral cavity. However, the efficacy and safety of LSFX in NHCAP treatment remains unknown. We aimed to evaluate the efficacy and safety of LSFX tablets in the treatment of patients with NHCAP.
METHODS:
In this single-arm, open-label, uncontrolled study, LSFX was administered to patients with NHCAP at 24 facilities. The study participants were orally administered 75 mg LSFX once daily for 7 days. The primary endpoint was the clinical efficacy at the time of test of cure (TOC). The secondary endpoints included clinical efficacy at the time of end of treatment (EOT), early clinical efficacy, microbiological efficacy, and safety analysis.
RESULT:
During the study period, 75 patients provided written informed consent to participate and were included. Finally, 56 and 71 patients were eligible for clinical efficacy and safety analyses, respectively. The median age of the patients was significantly high at 86 years. All patients were classified as having moderate disease severity using the A-DROP scoring system. LSFX tablets demonstrated high efficacy rates of 78.6 % at TOC and 89.3 % at EOT. The risk factors for resistant bacteria or aspiration pneumonia did not affect clinical efficacy. No severe adverse events associated with the study drugs were observed.
CONCLUSION:
Oral LSFX is an acceptable treatment option for moderate NHCAP in elderly patients who can take oral medications.
2024-07-01JOURNAL OF INFECTION AND CHEMOTHERAPY
Temporal effects of lascufloxacin on human gut and salivary microbiota: Analysis using next-generation sequencing method
Article
作者: Endo, Yusuke ; Yamasaki, Akira ; Chikumi, Hiroki ; Nakamoto, Masaki ; Doi, Ayumu ; Matsuda, Risa ; Morishima, So ; Okada, Kensaku ; Nishikawa, Yukari ; Mukuda, Kengo ; Ma'arif, Athok Shofiudin ; Oda, Machi ; Noma, Hisashi ; Kitaura, Tsuyoshi ; Sunada, Hiroshi ; Inoue, Ryo ; Takata, Miyako ; Takazawa, Kenji
INTRODUCTION:
Antimicrobial treatment disrupts human microbiota. The effects of lascufloxacin (LSFX), a new fluoroquinolone, on human microbiota remains unknown. Therefore, in this study, we aimed to evaluate the effects of LSFX administration on the gut and salivary microbiota of healthy participants and those with pneumonia.
METHODS:
LSFX (75 mg, once a day, orally) was administered to healthy adults (healthy group) and adult patients with pneumonia (pneumonia group), and fecal and saliva samples were collected at five time points (Days 0, 3, 7, 14, and 28). Using the collected samples, α- and β-diversity indices, as well as bacterial composition of the gut microbiota and salivary microbiota were analyzed using next-generation sequencing.
RESULTS:
In the healthy group, α-diversity indices of the gut and salivary microbiota were reduced and the lowest values on Day 3. For the gut microbiota, the Chao1 index (richness) recovered on Day 28, whereas the Shannon index (evenness) did not. In the salivary microbiota, the Chao1 and Shannon indices did not recover within the 28 day period. The β-diversity indices changed after LSFX administration and subsequently recovered on Day 28. After LSFX administration, the abundance of the Lachnospiraceae family decreased in the gut microbiota, and the abundance of Granulicatella, Streptococcus, Prevotella, Absconditabacteriales(SR1), and Saccharimonadales decreased in the salivary microbiota. In the pneumonia group, the α-diversity indices were lowest on Day 14 after LSFX administration.
CONCLUSIONS:
We elucidated that LSFX administration differentially affected the gut and salivary microbiota; however, the richness and beta diversity recovered within 28 days.
1
项与 Lascufloxacin Hydrochloride 相关的新闻（医药）100 项与 Lascufloxacin Hydrochloride 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10772 | Lascufloxacin Hydrochloride | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺脓肿 | 日本 | 2020-11-27 | |
| 肺炎 | 日本 | 2020-11-27 | |
| 呼吸道感染 | 日本 | 2020-11-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 下呼吸道感染 | 临床前 | 日本 | 2017-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用